India Takes Steps To End Branded Drug Name Confusion
This article was originally published in PharmAsia News
Indian authorities plan to establish a licensing board to approve names applied to branded drugs to end confusion over medicines with similar names. The Drug Controller General of India approves drugs marketed in the country, but names come under the authority of the Trade Marks Act and are licensed on the state level. The new licensing authority would be part of a broader plan to move manufacturing authority from the state to the federal level and a central agency. The chemical and health ministries already have given their approval to the proposed rearrangement. (Click here for more
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.